Found: 9
Select item for more details and to access through your institution.
Patient-centered applications: use of information technology to promote disease management and wellness. A white paper by the AMIA knowledge in motion working group.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Patient-centered Applications: Use of Information Technology to Promote Disease Management and Wellness. A White Paper by the AMIA Knowledge in Motion Working Group.
- Published in:
- Journal of the American Medical Informatics Association, 2008, v. 15, n. 1, p. 8, doi. 10.1197/jamia.M2492
- By:
- Publication type:
- Article
DEALE-ing with Lung Cancer and Heart Failure.
- Published in:
- Medical Decision Making, 2005, v. 25, n. 1, p. 82, doi. 10.1177/0272989X05274523
- By:
- Publication type:
- Article
Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S290, doi. 10.1016/j.clml.2019.07.236
- By:
- Publication type:
- Article
Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S289, doi. 10.1016/j.clml.2019.07.234
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S288, doi. 10.1016/j.clml.2019.07.232
- By:
- Publication type:
- Article
Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S287, doi. 10.1016/j.clml.2019.07.231
- By:
- Publication type:
- Article
ENESTfreedom 144-Week Update: Long-Term Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S226, doi. 10.1016/j.clml.2018.07.099
- By:
- Publication type:
- Article
Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S223, doi. 10.1016/j.clml.2018.07.094
- By:
- Publication type:
- Article